Abrocitinib
Brand Names: Cibinqo
Methodology & AI Transparency ⓘ
Abrocitinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 63539-336, 0069-0235 defines Abrocitinib (manufactured/labeled by U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 88% favorable across 12 logged regimens (Cibinqo).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $196.5694).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Abrocitinib: nausea (8.1%), headache (6.9%), dizziness (5%).
Ask our AI Specialists anything about Abrocitinib
Abrocitinib Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 63539-336, 0069-0235 defines Abrocitinib (manufactured/labeled by U.S. Pharmaceuticals) as a prescription-only oral-route janus kinase inhibitor available in 100 mg/1 Tablet, Film Coated and 50 mg/1 Tablet, Film Coated for individualized clinical regimens.
Clinical mechanism for Abrocitinib (100 mg/1 Tablet, Film Coated and 50 mg/1 Tablet, Film Coated, manufactured/labeled by U.S. Pharmaceuticals) centers on janus kinase inhibitor target modulation following oral-route uptake, maintaining therapeutic plasma exposure across FDA-listed 63539-336, 0069-0235 regimens.
Clinical clearance of Abrocitinib (Janus Kinase Inhibitor) relies on systemic clearance of abrocitinib integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 8 to 19 hours per Abrocitinib clinical pharmacology half-life; patients absorbing at Consistent 73%–85% gastrointestinal absorption profile for Abrocitinib bioavailability typically observe target onset around cmax attained 2–3 hours post-administration of abrocitinib.
FDA clinical labeling for Abrocitinib restricts administration in confirmed ige-mediated allergy or cutaneous reaction to abrocitinib (abrocitinib) components; uncompensated hepatic or renal insufficiency incompatible with abrocitinib (100 mg/1 tablet, film coated) clearance across 100 mg/1 Tablet, Film Coated, 50 mg/1 Tablet, Film Coated, 200 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by nausea (8.1% of reports), headache (6.9% of reports), dizziness (5% of reports).
Reconcile eGFR-adjusted medications before escalating Abrocitinib in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Abrocitinib dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Abrocitinib (Abrocitinib) components
- Uncompensated hepatic or renal insufficiency incompatible with Abrocitinib (100 mg/1 Tablet, Film Coated) clearance
Logged Side-Effect Incidence (12 Reports)
Abrocitinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Abrocitinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| Can This Approach Help? Inside the Latest Research on Sustained on/off-treatment disease control with abrocitinib for After 12 weeks of abrocitinib 200 mg, some patients achieved 40 weeks of sustained off-treatment disease control, with assessments demonstrating clear/mild AD, suggesting attainment of disease full symptom relief. The Journal of dermatological treatment • 2026-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42165315 ↗ |
| Cost per responder analysis of abrocitinib vs. Dupilumab: Which Works Better for Moderate to severe eczema? According to JADE COMPARE trial data, the costs per responder of abrocitinib were considerably lower than dupilumab. Italian journal of dermatology and venereology • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39250163 ↗ |
| Can This Approach Help? Inside the Latest Research on Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc Maintenance of response using reduced-dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38752592 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of abrocitinib single-drug treatment in adolescents and Abrocitinib was effective in preventing flare in adolescents and adults.Clinicaltrials.gov listing: NCT03627767. The Journal of dermatological treatment • 2023-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37036183 ↗ |
Abrocitinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $196.5694/unit (~$5897.08/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Abrocitinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Abrocitinib RxNorm Concept ID | RXN-63539336-2401 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $196.5694 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Abrocitinib Patient Community, Cohort Filters & Dosage Logs
Cross-verified Abrocitinib (janus kinase inhibitor) monograph synthesizing RxNorm RXN-63539336-2401, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Abrocitinib community threads and patient logs by age, biological sex, dosage, and treatment duration.